Apieron website screenshot

Apieron

Apieron Inc. was a private, venture-backed medical device company headquartered in Menlo Park, California, formed in early 2001 to develop a simple-to-use, non-invasive monitor for the measurement of exhaled nitric oxide (eNO) as an aid in the management of asthma. Its patented biosensor platform enabled highly sensitive detection of selected analytes, and its Insight eNO System received U.S. Food and Drug Administration clearance and launched in the United States in 2008. Following that launch Aerocrine filed patent-infringement complaints against Apieron and Apieron counterclaimed; citing the legal setbacks and a lack of financing, Apieron filed a Chapter 7 bankruptcy petition in the U.S. Bankruptcy Court for the Northern District of California on 30 March 2010. At a court auction on 12 May 2010 Aerocrine acquired all of Apieron's business assets, including its patent and trademark portfolio, ending the litigation; the Insight product was discontinued and not returned to supply. Apieron was a clinical-hardware company and never published a public API, developer portal, SDK, or machine-readable interface. This profile is retained as a historical record of the Canaan Partners portfolio and is not an active API provider.

Apieron is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Healthcare, Respiratory, and Asthma.

0 APIs
CompanyMedical DevicesHealthcareRespiratoryAsthmaDiagnosticsBiosensorsAcquiredHistorical

Resources

Other 1

Properties that don't map to a standard resource type

Source (apis.yml)

apis.yml Raw ↑
aid: apieron
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/apieron.png
name: Apieron
description: Apieron Inc. was a private, venture-backed medical device company headquartered in Menlo Park, California, formed
  in early 2001 to develop a simple-to-use, non-invasive monitor for the measurement of exhaled nitric oxide (eNO) as an aid
  in the management of asthma. Its patented biosensor platform enabled highly sensitive detection of selected analytes, and
  its Insight eNO System received U.S. Food and Drug Administration clearance and launched in the United States in 2008. Following
  that launch Aerocrine filed patent-infringement complaints against Apieron and Apieron counterclaimed; citing the legal
  setbacks and a lack of financing, Apieron filed a Chapter 7 bankruptcy petition in the U.S. Bankruptcy Court for the Northern
  District of California on 30 March 2010. At a court auction on 12 May 2010 Aerocrine acquired all of Apieron's business
  assets, including its patent and trademark portfolio, ending the litigation; the Insight product was discontinued and not
  returned to supply. Apieron was a clinical-hardware company and never published a public API, developer portal, SDK, or
  machine-readable interface. This profile is retained as a historical record of the Canaan Partners portfolio and is not
  an active API provider.
url: https://raw.githubusercontent.com/api-evangelist/apieron/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: historical
x-tier-reason: defunct-2010-no-api-surface
x-status: defunct
x-status-detail: Filed Chapter 7 bankruptcy 30 March 2010 (N.D. Cal.); all business assets, patents, and trademarks acquired
  by Aerocrine AB at a bankruptcy auction on 12 May 2010. The Insight eNO System was discontinued and not returned to supply.
x-acquired-by: Aerocrine AB
x-acquired-year: 2010
x-acquisition-type: bankruptcy-asset-sale
x-acquisition-source: https://www.globenewswire.com/news-release/2010/04/07/230395/0/en/Aerocrine-provides-update-on-its-legal-action-against-Apieron.html
x-acquirer-successor: Aerocrine AB was itself acquired by Circassia Pharmaceuticals plc in June 2015; Circassia Group plc
  rebranded to NIOX Group plc in 2022. aerocrine.com no longer resolves (probed 2026-07-19); the successor surface is https://www.niox.com/.
x-founded-year: 2001
x-headquarters: Menlo Park, California, United States
x-sector: Medical Devices
x-total-funding: $62.6 million
x-other-investors:
- Draper Fisher Jurvetson
- ONSET Ventures
- Technology Alliance Ventures
x-domain-status:
  domain: apieron.com
  probed: '2026-07-19'
  result: parked-for-sale
  note: 'apieron.com resolves and returns HTTP 200, but 307-redirects to a GoDaddy aftermarket for-sale lander. Every probed
    path returns the identical lander body: /.well-known/security.txt, /.well-known/openid-configuration, /.well-known/oauth-authorization-server,
    /.well-known/api-catalog and /.well-known/ai-plugin.json all byte-match the response for a randomly generated nonexistent
    path (md5 e89f75f918dbdcee28604d4e09dd71d7), so those 200 status codes are wildcard false positives and no well-known
    artifacts were saved. A /llms.txt is served but describes the GoDaddy domain listing rather than the company, and was
    likewise not saved.'
x-enrichment:
  date: '2026-07-19'
  status: nochange
  artifacts_added: 0
  pass: local-v1
  rationale: Searched and probed successfully. Entity is defunct (Chapter 7 in 2010; assets absorbed by Aerocrine) and published
    no API, developer portal, SDK, or specification during its operating life. Its former domain is now a GoDaddy for-sale
    parking page whose wildcard 200s were rejected as false positives. No artifacts were generated; fabricating any would
    be unfaithful.
x-disambiguation:
- name: Apeiron
  url: https://apeiron.io/
  relationship: unrelated-name-collision
  note: 'Apeiron (note the different spelling: "Apeiron", not "Apieron") is a present-day communications platform publishing
    voice/SIP trunking, SMS/MMS, phone number, E911 and cellular MVNE APIs with Postman collections at https://apeiron.io/docs.
    It is a separate company and is not the Canaan Partners portfolio company profiled here; its API surface must not be attributed
    to Apieron Inc.'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Medical Devices
- Healthcare
- Respiratory
- Asthma
- Diagnostics
- Biosensors
- Acquired
- Historical
apis: []
common:
- type: Acquirer
  name: Aerocrine AB (now NIOX Group plc)
  url: https://www.niox.com/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/apieron"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/apieron/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/apieron/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

A second provider on the same verified email joins the account you already have.